Literature DB >> 22108451

Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.

Alain Bitton1, Donald Buie, Robert Enns, Brian G Feagan, Jennifer L Jones, John K Marshall, Scott Whittaker, Anne M Griffiths, Remo Panaccione.   

Abstract

OBJECTIVES: The objective of this study was to provide updated explicit and relevant consensus statements for clinicians to refer to when managing hospitalized adult patients with acute severe ulcerative colitis (UC).
METHODS: The Canadian Association of Gastroenterology consensus group of 23 voting participants developed a series of recommendation statements that addressed pertinent clinical questions. An iterative voting and feedback process was used to do this in conjunction with systematic literature reviews. These statements were brought to a formal consensus meeting held in Toronto, Ontario (March 2010), when each statement was discussed, reformulated, voted upon, and subsequently revised until group consensus (at least 80% agreement) was obtained. The modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria were used to rate the strength of recommendations and the quality of evidence.
RESULTS: As a result of the iterative process, consensus was reached on 21 statements addressing four themes (General considerations and nutritional issues, Steroid use and predictors of steroid failure, Cyclosporine and infliximab, and Surgical issues).
CONCLUSIONS: Key recommendations for the treatment of hospitalized patients with severe UC include early escalation to second-line medical therapy with either infliximab or cyclosporine in individuals in whom parenteral steroids have failed after 72 h. These agents should be used in experienced centers where appropriate support is available. Sequential therapy with cyclosporine and infliximab is not recommended. Surgery is an option when first-line steroid therapy fails, and is indicated when second-line medical therapy fails and/or when complications arise during the hospitalization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108451     DOI: 10.1038/ajg.2011.386

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  50 in total

1.  Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients.

Authors:  Yan-Cheng Dai; Ya-Li Zhang; Li-Juan Wang; Qian Guo; Kun Yang; Ren-Hao Ye; Zhi-Peng Tang
Journal:  Chin J Integr Med       Date:  2015-10-26       Impact factor: 1.978

2.  Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis.

Authors:  Eun Soo Kim; Kyeong Ok Kim; Byung Ik Jang; Eun Young Kim; Yoo Jin Lee; Hyun Seok Lee; Seong Woo Jeon; Hyun Jin Kim; Sung Kook Kim
Journal:  Dig Dis Sci       Date:  2017-06-21       Impact factor: 3.199

3.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The patient perspective.

Authors:  A Hillary Steinhart; Aida Fernandes
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05-22

Review 4.  A product review of vedolizumab in inflammatory bowel disease.

Authors:  Robert Battat; Parambir S Dulai; Vipul Jairath; Niels Vande Casteele
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

5.  Management of Hospitalized Patients With Ulcerative Colitis.

Authors:  Leonard Baidoo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-03

Review 6.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.

Authors:  Robert Battat; Christopher Ma; Vipul Jairath; Reena Khanna; Brian G Feagan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

7.  Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.

Authors:  Jessica Breton; Arthur Kastl; Natalie Hoffmann; Rachel Rogers; Andrew B Grossman; Petar Mamula; Judith R Kelsen; Robert N Baldassano; Lindsey Albenberg
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

Review 8.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 9.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

10.  Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors.

Authors:  Elizabeth A Scoville; Gauree G Konijeti; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.